A rare and devastating inherited immune disorder may have a new path toward treatment, thanks to a proof-of-concept study demonstrating that CRISPR base editors can correct disease-causing mutations in the Artemis gene outside the body. Artemis-deficient severe combined immunodeficiency, known as ART-SCID, leaves infants with almost no functional T and B cells, and current treatments […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.